I am open to being pleasantly surprised by any additional news that might be in the pipeline e.g., roll out of more NHS trusts for the hearing loss product, new distributors around the world, or news of the FDA pre-sub meeting.
NICE news remains the big one that we are all hoping for in February and funding is 2023s ELEPHANT in the room.
Great to see +13% but i just don't know what's behind it.
I can't see this being on the back of the NCYT rise as we can't be described as a COVID stock (as we haven't sold any COVID products).
The only thing i can think of would be news of a preliminary meeting with the FDA with regards to the hearing loss product. This was pencilled in for December 2022 in the Final Results presentation.
Would be good to see an RNS of some sort come out of the AGM to keep everyone updated.
There are roughly 88,000 babies born in Austria per year. Going by the European average one in ten shall be born pre-term. The full market potential is therefore around 8 to 9 thousand per year.